AQR Capital Management LLC Decreases Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

AQR Capital Management LLC decreased its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 10.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,015 shares of the company’s stock after selling 353 shares during the period. AQR Capital Management LLC’s holdings in TransMedics Group were worth $454,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of TMDX. Fidelis Capital Partners LLC purchased a new position in TransMedics Group during the first quarter valued at approximately $35,000. International Assets Investment Management LLC purchased a new stake in shares of TransMedics Group in the 2nd quarter worth about $47,000. J.Safra Asset Management Corp grew its position in shares of TransMedics Group by 649.2% in the 2nd quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock worth $67,000 after buying an additional 383 shares during the period. Signaturefd LLC grew its position in shares of TransMedics Group by 26.6% in the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after buying an additional 93 shares during the period. Finally, Amalgamated Bank grew its position in shares of TransMedics Group by 6.7% in the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after buying an additional 70 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In other TransMedics Group news, Director James R. Tobin sold 20,000 shares of the firm’s stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the sale, the director now directly owns 173,146 shares of the company’s stock, valued at approximately $27,587,352.18. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director James R. Tobin sold 20,000 shares of TransMedics Group stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $159.33, for a total value of $3,186,600.00. Following the transaction, the director now directly owns 173,146 shares of the company’s stock, valued at $27,587,352.18. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Nicholas Corcoran sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 55,580 shares of company stock worth $8,837,283. 7.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on TMDX shares. Morgan Stanley boosted their price objective on shares of TransMedics Group from $104.00 to $145.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Oppenheimer increased their price objective on shares of TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, August 1st. Baird R W upgraded shares of TransMedics Group to a “strong-buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group increased their target price on shares of TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research note on Thursday, August 1st. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $180.00 price target on shares of TransMedics Group in a research note on Monday, October 7th. One analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $174.30.

TransMedics Group Stock Performance

Shares of TransMedics Group stock opened at $131.84 on Wednesday. The firm has a market capitalization of $4.34 billion, a P/E ratio of -387.76 and a beta of 1.99. TransMedics Group, Inc. has a 52 week low of $36.42 and a 52 week high of $177.37. The company has a quick ratio of 8.48, a current ratio of 9.37 and a debt-to-equity ratio of 2.67. The firm’s 50 day moving average is $154.43 and its two-hundred day moving average is $137.60.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.14. The business had revenue of $114.30 million during the quarter, compared to the consensus estimate of $98.84 million. TransMedics Group had a return on equity of 15.98% and a net margin of 0.84%. The company’s revenue was up 117.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.03) earnings per share. Research analysts forecast that TransMedics Group, Inc. will post 1.22 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.